Stock Events

Stock Events

Zelluna ASA 

SEK21.95
0
+SEK0+0% Tuesday 08:00

Statistics

Day High
-
Day Low
-
52W High
21.95
52W Low
2.1
Volume
-
Avg. Volume
0
Mkt Cap
448.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2021
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-15.18
-14.84
-14.51
-14.18
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-394.22MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ULTIO.ST. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE is a competitor because it focuses on developing immunotherapies for cancer and other serious diseases, similar to Ultimovacs' focus on cancer vaccine development.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. is involved in creating mRNA-based therapies and vaccines, including for cancer, which competes with Ultimovacs' cancer vaccine research.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc. competes in the vaccine space, including efforts in developing vaccines that could potentially overlap with Ultimovacs' cancer vaccine initiatives.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. has a broad portfolio in oncology and immunotherapy, areas that are directly competitive with Ultimovacs' cancer treatment research.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotechnology company with a focus on cancer and human therapeutics, which competes with Ultimovacs' work in cancer vaccines.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company has a strong presence in cancer immunotherapy, making it a direct competitor to Ultimovacs' cancer vaccine development.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a leading company in cancer immunotherapy, particularly with its successful PD-1 inhibitor, competing in the same space as Ultimovacs.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a diverse portfolio including oncology and vaccine development, areas where it competes with Ultimovacs.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong focus on oncology, including immunotherapy and vaccines, making it a competitor to Ultimovacs.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, is involved in developing treatments for various cancers, competing with Ultimovacs' cancer vaccine efforts.

About

Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers. The company was founded in 2016 and is based in Oslo, Norway.
Show more...
CEO
ISIN
NO0013524942

Listings

ST
SE
ULTIO.ST
OL
NO
ZLNA.OL
F
DE
7UM0.F

0 Comments

Share your thoughts

FAQ

What is Zelluna ASA stock price today?▼
The current price of ULTIO.ST is SEK21.95 SEK — it has increased by +0% in the past 24 hours. Watch Zelluna ASA stock price performance more closely on the chart.
What is Zelluna ASA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Zelluna ASA stocks are traded under the ticker ULTIO.ST.
What is Zelluna ASA market cap?▼
Today Zelluna ASA has the market capitalization of 448.97M
When is the next Zelluna ASA earnings date?▼
Zelluna ASA is going to release the next earnings report on May 07, 2026.
What is Zelluna ASA revenue for the last year?▼
Zelluna ASA revenue for the last year amounts to 0 SEK.
What is Zelluna ASA net income for the last year?▼
ULTIO.ST net income for the last year is -394.22M SEK.
When did Zelluna ASA complete a stock split?▼
Zelluna ASA has not had any recent stock splits.